217 related articles for article (PubMed ID: 19738127)
1. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology.
Brugières L; Pacquement H; Le Deley MC; Leverger G; Lutz P; Paillard C; Baruchel A; Frappaz D; Nelken B; Lamant L; Patte C
J Clin Oncol; 2009 Oct; 27(30):5056-61. PubMed ID: 19738127
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
3. Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine.
Garner R; Li Y; Gray B; Zori R; Braylan R; Wall J; Hunger SP
J Pediatr Hematol Oncol; 2009 Feb; 31(2):145-7. PubMed ID: 19194204
[TBL] [Abstract][Full Text] [Related]
4. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan.
Mori T; Takimoto T; Katano N; Kikuchi A; Tabuchi K; Kobayashi R; Ayukawa H; Kumagai MA; Horibe K; Tsurusawa M
Br J Haematol; 2006 Mar; 132(5):594-7. PubMed ID: 16445832
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
7. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan.
Mitsui T; Mori T; Fujita N; Inada H; Horibe K; Tsurusawa M;
Pediatr Blood Cancer; 2009 May; 52(5):591-5. PubMed ID: 19156862
[TBL] [Abstract][Full Text] [Related]
9. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Knörr F; Brugières L; Pillon M; Zimmermann M; Ruf S; Attarbaschi A; Mellgren K; Burke GAA; Uyttebroeck A; Wróbel G; Beishuizen A; Aladjidi N; Reiter A; Woessmann W;
J Clin Oncol; 2020 Dec; 38(34):3999-4009. PubMed ID: 32730187
[TBL] [Abstract][Full Text] [Related]
10. Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide.
Stockklausner C; Behnisch W; Mechtersheimer G; Möller P; Kulozik AE
Pediatr Blood Cancer; 2008 Jan; 50(1):126-9. PubMed ID: 16609950
[TBL] [Abstract][Full Text] [Related]
11. Successful outcome of patients with relapsed/refractor Hodgkin lymphoma treated with high dose chemotherapy at the National Adult Bone Marrow Transplant Unit at St. James's Hospital.
Bacon CL; Daly P; Sheane B; Conneally EC; Browne PV; McCann S; Ni Chongaile M; O'Brian DS; Mc Dermott R; Hollywood D; Wilson L; Vandenberghe E
Ir Med J; 2009 Jan; 102(1):26-8. PubMed ID: 19284016
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
14. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
[TBL] [Abstract][Full Text] [Related]
16. Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases.
Spiegel A; Paillard C; Ducassou S; Perel Y; Plantaz D; Strullu M; Eischen A; Lutz P; Lamant L; Le Deley MC; Brugières L
Br J Haematol; 2014 May; 165(4):545-51. PubMed ID: 24666317
[TBL] [Abstract][Full Text] [Related]
17. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.
O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J
Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM; Lossos IS; Justice G; Vose JM; Wiernik PH; McBride K; Wride K; Ervin-Haynes A; Takeshita K; Pietronigro D; Zeldis JB; Tuscano JM
Br J Haematol; 2009 May; 145(3):344-9. PubMed ID: 19245430
[TBL] [Abstract][Full Text] [Related]
19. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
20. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
Ruf S; Hebart H; Hjalgrim LL; Kabickova E; Lang P; Steinbach D; Schwabe GC; Woessmann W
Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
